Creatinine for Interference Testing Catalog # K2010008C Lot # Batch Dependent Expiration Batch Dependent Volume 1 mL Appearance Clear solution Concentration 50 mg/mL in diluent A (provided) Molar Mass 113.12 g/mol Storage –20°C or lower; avoid freeze-thaw cycles Other Names 2-Amino-1-methyl-2-imidazolin-4-one, 2-Imino-N-methylhydantoin This high-purity creatinine solution (50 mg/mL) is formulated in diluent A and optimized for interference testing in immunoassays and clinical chemistry workflows. Creatinine is a low-molecular-weight compound commonly used to evaluate assay specificity and robustness against endogenous interference. Its well-characterized structure and consistent behavior across platforms make it a reliable standard for validating analytical performance. Supplied as a clear solution in 1 mL aliquots, this reagent is ideal for spike-in studies, matrix effect evaluations, and interference profiling. It is compatible with ELISA, CLIA, and other immunoassay formats. The product is filtered and aliquoted for long-term storage at –20°C. Avoid repeated freeze-thaw cycles to preserve integrity. Diluent A is included for convenience and reproducibility. Key benefits: 50 mg/mL creatinine solution for interference testing Validated for immunoassay and clinical chemistry workflows Supplied in diluent A; ready-to-use format Aliquoted for long-term storage at –20°C Supports assay validation, spike-in studies, and matrix effect analysis Indication for Use:This product is for Research Use Only (RUO). This product is not for administration to humans or animals. This product is not for human or veterinary diagnostic or therapeutic use. All Interference Products Brochure: References: Schiettecatte J, Anckaert E, Smitz J. Interferences in Immunoassays. Advances in Immunoassay Technology, 2012. Miller JJ, Levinson SS. Interferences In Immunoassays. Immunoassay, 1996;165–190. Ward G. Rational investigations of immunoassay interferences. Pathology, 2013;45. Park JY, Kricka LJ. Interferences in Immunoassay. The Immunoassay Handbook, 2013;403–416. CLSI EP07: Interference Testing in Clinical Chemistry. 2020. CLSI.org Gilles A et al. Targeting the Human 80S Ribosome in Cancer. Cells. 2020;9(3):E629. Coussens NP et al. Compound-Mediated Assay Interferences. Assay Guidance Manual, 2020. Wang L et al. Fluorescent probes for nitric oxide. Org Biomol Chem. 2020;18(8):1522–1549. Kawasaki H et al. Drosophila GBA mutant phenotypes. Gene. 2017;614:49–55. Hull B. HAMA interference in TSH assay. J S C Med Assoc. 2012;108(1):12–13. Degn SE et al. Rat kappa light-chain interference. J Immunol Methods. 2011;372(1–2):204–208.
